Cell selection and characterization of a novel human endothelial cell specific nanobody, Molecular Immunology, vol.46, issue.8-9, pp.8-9, 2009. ,
DOI : 10.1016/j.molimm.2009.01.021
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies, FEBS Letters, vol.15, issue.3, pp.521-526, 1997. ,
DOI : 10.1016/S0014-5793(97)01062-4
Targeting Endothelial Cells Overexpressing VEGFR-2:?? Selective Toxicity of Shiga-like Toxin???VEGF Fusion Proteins, Bioconjugate Chemistry, vol.12, issue.6, pp.1066-1073, 2001. ,
DOI : 10.1021/bc015534j
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status, Current Oncology Reports, vol.9, issue.2, pp.103-111, 2011. ,
DOI : 10.1007/s11912-011-0154-3
Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR), Journal of Immunological Methods, vol.300, issue.1-2, pp.1-2, 2005. ,
DOI : 10.1016/j.jim.2005.03.007
Contributions of CDR3 to VHH Domain Stability and the Design of Monobody Scaffolds for Naive Antibody Libraries, Journal of Molecular Biology, vol.332, issue.3, pp.643-655, 2003. ,
DOI : 10.1016/S0022-2836(03)00967-7
Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor, Journal of Thrombosis and Haemostasis, vol.283, issue.6, pp.1302-1312, 2010. ,
DOI : 10.1111/j.1538-7836.2010.03816.x
Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae, Antimicrob. Agents Chemother, issue.10, pp.45-2807, 2001. ,
Biological Activity and Phosphorylation Sites of the Bacterially Expressed Cytosolic Domain of the KDR VEGF-Receptor, Biochemical and Biophysical Research Communications, vol.205, issue.1, pp.728-738, 1994. ,
DOI : 10.1006/bbrc.1994.2726
Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol, Molecular Immunology, vol.45, issue.14, pp.45-3703, 2008. ,
DOI : 10.1016/j.molimm.2008.06.005
VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-591, 2008. ,
DOI : 10.1038/nrc2403
VEGF-A: a critical regulator of blood vessel growth, Eur. Cytokine Netw, vol.20, issue.4, pp.158-163, 2009. ,
Anti-Angiogenesis, Annals of Surgery, vol.175, issue.3, pp.409-416, 1972. ,
DOI : 10.1097/00000658-197203000-00014
Angiogenesis: an organizing principle for drug discovery?, Nature Reviews Drug Discovery, vol.57, issue.5, pp.273-286, 2007. ,
DOI : 10.1038/nrd2115
Facile Generation of Heat-Stable Antiviral and Antitoxin Single Domain Antibodies from a Semisynthetic Llama Library, Analytical Chemistry, vol.78, issue.24, pp.78-8245, 2006. ,
DOI : 10.1021/ac0610053
A bispecific nanobody to provide full protection against lethal scorpion envenoming, The FASEB Journal, vol.24, issue.9, pp.3479-3489, 2010. ,
DOI : 10.1096/fj.09-148213
URL : https://hal.archives-ouvertes.fr/pasteur-00612182
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition, Cellular Signalling, vol.19, issue.10, pp.2003-2012, 2007. ,
DOI : 10.1016/j.cellsig.2007.05.013
A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes, Cytotechnology, vol.17, issue.1, pp.61-71, 2010. ,
DOI : 10.1007/s10616-010-9262-4
An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2-Dependent Angiogenesis without Affecting Ligand Binding, Molecular Cancer Therapeutics, vol.10, issue.5, pp.770-783, 2011. ,
DOI : 10.1158/1535-7163.MCT-10-0876
In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment, Experimental and Molecular Pathology, vol.76, issue.2, pp.129-137, 2004. ,
DOI : 10.1016/j.yexmp.2003.10.010
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiationinduced long-term control of human tumor xenografts, Cancer Res, vol.61, issue.1, pp.39-44, 2001. ,
Single-domain antibodies recognize selectively small oligomeric forms of amyloid ??, prevent A??-induced neurotoxicity and inhibit fibril formation, Molecular Immunology, vol.46, issue.4, pp.695-704, 2009. ,
DOI : 10.1016/j.molimm.2008.09.008
IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains, Developmental & Comparative Immunology, vol.29, issue.3, pp.185-203, 2005. ,
DOI : 10.1016/j.dci.2004.07.003
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy, International Journal of Cancer, vol.19, issue.3, pp.393-399, 2002. ,
DOI : 10.1002/ijc.1634
Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action, Journal of Investigative Dermatology, vol.131, issue.6, pp.1356-1364, 2011. ,
DOI : 10.1038/jid.2011.46
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2, Biochemical and Biophysical Research Communications, vol.345, issue.1, pp.438-445, 2006. ,
DOI : 10.1016/j.bbrc.2006.04.119
Single domain camel antibodies: current status, Reviews in Molecular Biotechnology, vol.74, issue.4, pp.277-302, 2001. ,
DOI : 10.1016/S1389-0352(01)00021-6
Camelid immunoglobulins and nanobody technology, Veterinary Immunology and Immunopathology, vol.128, issue.1-3, pp.1-3, 2009. ,
DOI : 10.1016/j.vetimm.2008.10.299
Downregulation of EGFR by a novel multivalent nanobody-liposome platform, Journal of Controlled Release, vol.145, issue.2, pp.165-175, 2010. ,
DOI : 10.1016/j.jconrel.2010.03.020
VEGF receptor signalling ??? in control of vascular function, Nature Reviews Molecular Cell Biology, vol.99, issue.5, pp.359-371, 2006. ,
DOI : 10.1038/nrm1911
Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in <i>Camelus bactrianus</i>, Tumor Biology, vol.13, issue.4, pp.179-187, 2004. ,
DOI : 10.1002/ijc.10189
Nanobody; an Old Concept and New Vehicle for Immunotargeting, Immunological Investigations, vol.42, issue.28, pp.299-338, 2011. ,
DOI : 10.1016/S0001-2998(97)80033-5
Production of Novel Recombinant Single-Domain Antibodies against Tandem Repeat Region of MUC1 Mucin, Hybridoma and Hybridomics, vol.23, issue.3, pp.151-159, 2004. ,
DOI : 10.1089/1536859041224334
The Discovery of Antiangiogenic Molecules: A Historical Review, Current Pharmaceutical Design, vol.15, issue.4, pp.345-352, 2009. ,
DOI : 10.2174/138161209787315855
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies, Cancer Immunology, Immunotherapy, vol.2, issue.11, pp.303-317, 2007. ,
DOI : 10.1007/s00262-006-0180-4
VEGF receptor protein-tyrosine kinases: structure and regulation, Biochem. Biophys. Res. Commun, vol.375, issue.3, pp.287-291, 2008. ,
Single-domain antibodies as building blocks for novel therapeutics, Current Opinion in Pharmacology, vol.8, issue.5, pp.600-608, 2008. ,
DOI : 10.1016/j.coph.2008.07.006
Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2, Current Oncology Reports, vol.17, issue.3, pp.97-102, 2011. ,
DOI : 10.1007/s11912-010-0149-5
Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, pp.780-787, 2010. ,
DOI : 10.1200/JCO.2009.23.7537
Ramucirumab (IMC-1121B): a novel attack on angiogenesis, Future Oncology, vol.6, issue.7, pp.1085-1094, 2010. ,
DOI : 10.2217/fon.10.75
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods, Molecular Biology and Evolution, vol.28, issue.10, pp.28-2731, 2011. ,
DOI : 10.1093/molbev/msr121
In vitro antiviral activity of single domain antibody fragments against poliovirus, Antiviral Research, vol.87, issue.2, pp.257-264, 2010. ,
DOI : 10.1016/j.antiviral.2010.05.012
Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1, Biochemical and Biophysical Research Communications, vol.408, issue.4, pp.692-696, 2011. ,
DOI : 10.1016/j.bbrc.2011.04.090
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model, Clin. Cancer Res, vol.11, issue.1, pp.407-409, 2005. ,
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy, Clinical Cancer Research, vol.13, issue.18, pp.5544-5548, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-1107
Targeting cancer with small molecule kinase inhibitors, Nature Reviews Cancer, vol.62, issue.1, pp.28-39, 2009. ,
DOI : 10.1016/S0092-8674(03)00194-6